Press Release: Novartis Kisqali(R) shows -2-

can there be any guarantee that such products will be commercially successful in the future. In particular, our expectations regarding such products could be affected by, among other things, the uncertainties inherent in research and development, including clinical trial results and additional analysis of existing clinical data; regulatory actions or delays or government regulation generally; global trends toward health care cost containment, including government, payor and general public pricing and reimbursement pressures and requirements for increased pricing transparency; our ability to obtain or maintain proprietary intellectual property protection; the particular prescribing preferences of physicians and patients; general political, economic and business conditions, including the effects of and efforts to mitigate pandemic diseases; safety, quality, data integrity or manufacturing issues; potential or actual data security and data privacy breaches, or disruptions of our information technology systems, and other risks and factors referred to in Novartis AG's current Form 20-F on file with the US Securities and Exchange Commission. Novartis is providing the information in this media update as of this date and does not undertake any obligation to update any forward-looking statements contained in this media update as a result of new information, future events or otherwise.

About Novartis

Novartis is an innovative medicines company. Every day, we work to reimagine medicine to improve and extend people's lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide.

Reimagine medicine with us: Visit us at https://www.novartis.com/ https://www.novartis.com and connect with us on https://www.linkedin.com/company/novartis/ LinkedIn, https://www.facebook.com/novartis/ Facebook, https://twitter.com/Novartis X/Twitter and https://instagram.com/novartis?igshid=MzRlODBiNWFlZA==__;!!N3hqHg43uw!pjp8z253J5NjaOYrW65UbAAlHeHRdQ-w0m4ezZxEQEl0ptafXN2M99VRIk39pf49PAc8NbK93Pxp3uaSBQkAf8oEnzWXG8Sk$ Instagram.

References

1. Fasching PA. Adjuvant Ribociclib (RIB) Plus Nonsteroidal Aromatase

Inhibitor (NSAI) in Patients (Pts) With HR+/HER2- Early Breast Cancer

(EBC): 4-Year Outcomes From the NATALEE Trial. LBA13. Proffered Paper

presented at the European Society for Medical Oncology Congress,

September 16, 2024. Barcelona, Spain.

2. Pan H, Gray R, Braybrooke J, et al. 20-Year Risks of Breast-Cancer

Recurrence after Stopping Endocrine Therapy at 5 Years. N Engl J Med.

2017;377(19):1836-1846.

3. Yardley D et al. Baseline (BL) characteristics and efficacy endpoints for

patients (pts) with node-negative (N0) HR+/HER2- early breast cancer

(EBC) in NATALEE. Presented at the American Society of Clinical Oncology

Annual Meeting, May 31, 2024. Chicago, USA.

4. Slamon D, Lipatov O, Nowecki Z, et al. Ribociclib plus Endocrine Therapy

in Early Breast Cancer. N Engl J Med. 2024;390(12):1080-1091.

doi:10.1056/NEJMoa2305488

5. Clinicaltrials.gov. NCT03701334. A Trial to Evaluate Efficacy and Safety

of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients

With HR+/ HER2- Early Breast Cancer (NATALEE). Available from:

https://clinicaltrials.gov/study/NCT03701334. Accessed August 2024.

6. Kisqali. Prescribing Information (US FDA). Novartis Pharmaceuticals

Corporation; 2017. Accessed July 2024.

https://www.novartis.com/us-en/sites/novartis_us/files/kisqali.pdf

7. Kisqali. Summary of product characteristics (SmPC). Novartis Europharm

Limited; 2017. Accessed August 2024.

https://www.ema.europa.eu/en/documents/product-information/kisqali-epar-product-information_en.pdf

8. Yardley DA et al. Pooled exploratory analysis of survival in patients

(pts) with HR+/HER2- advanced breast cancer (ABC) and visceral metastases

(mets) treated with ribociclib (RIB) + endocrine therapy (ET) in the

MONALEESA (ML) trials. Poster presented at the European Society of

Medical Oncology Congress. September 9-13, 2022. Paris, France.

9. Neven P et al. Updated overall survival (OS) results from the first-line

(1L) population in the Phase III MONALEESA-3 trial of postmenopausal

patients with HR+/HER2- advanced breast cancer (ABC) treated with

ribociclib (RIB) + fulvestrant (FUL). Mini oral presented at the European

Society for Medical Oncology Breast Cancer Congress. May 4, 2022. Paris,

France.

10. Hortobagyi GN, Stemmer SM, Burris HA, et al. Overall Survival with

Ribociclib plus Letrozole in Advanced Breast Cancer. N Engl J Med.

2022;386(10):942-950. doi:10.1056/NEJMoa2114663

11. Hortobagyi GN et al. Overall survival (OS) results from the phase III

MONALEESA (ML)-2 trial of postmenopausal patients with hormone receptor

positive/human epidermal growth factor receptor 2 negative (HR+/HER2-)

advanced breast cancer (ABC) treated with endocrine therapy (ET) +/-

ribociclib. LBA 17. Proffered paper presented at the European Society of

Medical Oncology Congress, September 16-21, 2021. Lugano, Switzerland.

12. Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus

endocrine therapy in breast cancer. N Engl J Med. 2019;381(4):307-316.

doi:10.1056/NEJMoa1903765

13. Slamon DJ, Neven P, Chia S, et al. Overall Survival with Ribociclib plus

Fulvestrant in Advanced Breast Cancer. N Engl J Med. 2020;382(6):514-524.

doi:10.1056/NEJMoa1911149

14. Slamon DJ et al. Overall survival (OS) results of the Phase III

MONALEESA-3 trial of postmenopausal patients (pts) with hormone

receptor-positive (HR+), human epidermal growth factor 2-negative (HER2-)

advanced breast cancer (ABC) treated with fulvestrant (FUL) +/-

ribociclib (RIB). LBA7_PR. Presented at the European Society of Medical

Oncology Congress, September 29, 2019. Barcelona, Spain.

15. Slamon DJ et al. Updated overall survival (OS) results from the Phase III

MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2-

advanced breast cancer (ABC) treated with fulvestrant (FUL) +/-

ribociclib (RIB). Presented at the American Society of Clinical Oncology

Annual Meeting, June 5, 2021. Chicago, USA.

16. Tripathy D et al. Updated overall survival (OS) results from the phase

III MONALEESA-7 trial of pre- or perimenopausal patients with HR+/HER2-

advanced breast cancer (ABC) treated with endocrine therapy (ET) +/-

ribociclib. Presented at the San Antonio Breast Cancer Symposium,

December 9, 2020. Texas, USA.

17. Yardley D et al. Overall survival (OS) in patients (pts) with advanced

breast cancer (ABC) with visceral metastases (mets), including those with

liver mets, treated with ribociclib (RIB) plus endocrine therapy (ET) in

the MONALEESA (ML) -3 and -7 trials. Presented at the American Society of

Clinical Oncology Annual Meeting, June 2020. Chicago, USA.

18. O'Shaughnessy J et al. Overall survival subgroup analysis by metastatic

site from the Phase III MONALEESA-2 study of first-line ribociclib +

letrozole in postmenopausal patients with HR+/HER2- advanced breast

cancer. Presented at the San Antonio Breast Cancer Symposium, December

7-10, 2021. Texas, USA.

19. NCCN Guidelines. NCCN Clinical Practice Guidelines in Oncology (NCCN

Guidelines(R)) - Breast Cancer. Accessed July 2024.

20. European Society for Medical Oncology. Magnitude of Clinical Benefit

Scale Scorecard. Accessed July 2024.

https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-158-1

21. European Society for Medical Oncology. Magnitude of Clinical Benefit

Scale Scorecard. Accessed July 2024.

https://www.esmo.org/guidelines/esmo-mcbs/esmo-mcbs-scorecards/scorecard-9-1

# # #

Novartis Media Relations

E-mail: media.relations@novartis.com

Central North America

Anja von Treskow +41 79 392 9697 Michael Meo +1 862 274 5414

Anna Schäfers +41 79 801 7267

Switzerland

Satoshi Sugimoto +41 79 619 2035

Novartis Investor Relations

Central investor relations line: +41 61 324 7944

E-mail: investor.relations@novartis.com

Central North America

Isabella Zinck +41 61 324 7188 Sloan Simpson +1 862 345 4440

Nicole Zinsli-Somm +41 61 324 3809 Jonathan Graham +1 201 602 9921

Imke Kappes +41 61 324 8269 Parag Mahanti +1 973 876 4912

(END) Dow Jones Newswires

September 16, 2024 04:15 ET (08:15 GMT)